Welcome to the Stanford Division of Hematology, a dynamic center for basic and translational research, clinical trials, patient care, and teaching. Our physicians, scientists, staff, and trainees collaborate to advance the understanding and treatment of hematologic disorders, all with the goal of improving outcomes for patients with these diseases. In pursuit of this objective, we engage with the broader Stanford community to bring innovation to our efforts.

Over the last 20 years, multiple novel therapies have resulted in significant clinical advances for hematologic diseases, and Stanford investigators have played key roles in their development, including imatinib for CML, ibrutinib for CLL, midostaurin for mast cell disease, and many others. Our clinicians have expertise in a broad range of hematologic disorders including acute and chronic leukemias, myeloproliferative neoplasms, myelodysplastic syndromes, multiple myeloma, amyloidosis, thrombotic diseases, coagulation disorders, and general hematology.

The basic and translational research efforts of the division have led to fundamental discoveries in areas as diverse as leukemia & stem cells, genomics, thrombosis, telomere & cancer biology, and the microbiome. Our passionate faculty members have mentored and trained leaders in the field of hematology and are committed to attract the next generation of leading physicians and research scientists. We invite you to learn more about us through our website.

Welcome Priya Vader

the new Administrative Division Director Hematology

Prior to joining Stanford, Priya worked at Mass General Hospital and MGB (Partners) hospitals in the Boston area for more than 15 yrs. Priya did her medical schooling from India and MHA from University of Pittsburgh. Priya said, “I am excited to join the Hematology division and to be part of an amazing team of faculty and staff.”

Rondeep Brar, MD, Named Medical Director for Cancer DSL & SCI’s Assoc. Director for Clinical Care

Dear Colleagues,

We are delighted to announce that Rondeep (Roni) Brar, MD, clinical associate professor of Medicine, has been appointed Stanford Health Care’s Medical Director for the Cancer Destination Service Line (DSL) and Stanford Cancer Institute’s Associate Director for Clinical Care. He began in these dual roles on Monday, February 6.

Over the last decade, Dr. Brar has shown tremendous vision in re-imagining and elevating our health system’s inpatient cancer care services and ambulatory hematology practice. This includes engaging with and leading teams to redesign the Advanced Practice Provider (APP) system, improve inpatient documentation, grow patient volumes, and increase and diversify clinical trial enrollments.

These successes are a testament to Dr. Brar’s strong leadership, expansive expertise, cutting-edge clinical research, and compassionate care. They also reflect his vast institutional knowledge and the strong collegial relationships he has formed across Stanford Medicine. 

After receiving his MD from UCLA in 2007, Dr. Brar completed his internal medicine residency at Stanford in 2010, and his fellowships in hematology and oncology at Stanford in 2012. Dr. Brar was then recruited as a Clinical Assistant Professor in the Department of Medicine, Division of Hematology in 2012. He was subsequently promoted to Clinical Associate Professor in 2018.

Since August 2021, alongside Heather Wakelee, MD, Dr. Brar has served as the Interim Medical Co-Director of the Cancer DSL. During this time, Drs. Brar and Wakelee have re-aligned the structure and leadership of the Cancer Care Programs, reconfigured the leadership cabinet to represent a broader constituent group, and engaged in strategic planning for our joint ventures and future campus expansion.

Dr. Brar will work closely with Drs. Artandi and Seshadri as well as Maria Gonzalez, Executive Director of the Cancer DSL, to shape and implement the future of the Cancer DSL.

Dr. Wakelee will continue to provide interim support through March 2023 as Dr. Brar transitions some of his clinical operations. We want to thank Dr. Wakelee for her dedication and stellar leadership as she continues her exemplary service as the Division Chief of Medical Oncology and Deputy Director of SCI and for her extensive work in enhancing cancer clinical trials.

We also want to express our gratitude to our search committee and the stakeholders across Stanford Medicine who helped facilitate this important search.

We are excited to have Dr. Brar serve in these leadership roles and look forward to his contributions. Please join us in congratulating Dr. Brar on this well-deserved recognition.

Sincerely, 

Steve, Sri, and Niraj